Avalyn Pharma, Inc.

Iambic Therapeutics is the latest biopharmaceutical company to raise a venture capital mega-round in support of an artificial intelligence-powered drug discovery platform and emerging clinical-stage

Biopharmaceutical companies raised $3.95bn in venture capital globally during the third quarter of 2023, but firms raising small and large rounds brought in far less cash during the quarter compared t

Who: Avalyn Pharma Funding round: $175m series C, announced on 27 September Investors: Perceptive Xontogeny Venture Funds, SR One and Eventide Asset Management co-led the round. They were joined

PureTech Health plc will start a dose-ranging study of LYT-100, a modified version of Roche Holding AG ’s idiopathic pulmonary fibrosis (IPF) blockbuster Esbriet as part of its plan to advance the c